Journal of Health Economics and Outcomes Research最新文献_第4页

Cryoballoon Ablation With the POLARx FIT or the Arctic Front Advance Pro for Paroxysmal Atrial Fibrillation: A Health Economic Analysis. 使用polar FIT或Arctic Front Advance Pro冷冻球囊消融治疗阵发性心房颤动：健康经济学分析。

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-04-21 eCollection Date: 2025-01-01 DOI: 10.36469/001c.133223

Luigi Pannone, Steffen Uffenorde, Antonia Bosworth Smith, Domenico Giovanni Della Rocca, Pasquale Vergara, Ioannis Doundoulakis, Antonio Sorgente, Alvise Del Monte, Giacomo Talevi, Ingrid Overeinder, Gezim Bala, Alexandre Almorad, Erwin Ströker, Juan Sieira, Ali Gharaviri, Mark La Meir, Pedro Brugada, Andrea Sarkozy, Gian Battista Chierchia, Carlo de Asmundis

{"title":"Cryoballoon Ablation With the POLARx FIT or the Arctic Front Advance Pro for Paroxysmal Atrial Fibrillation: A Health Economic Analysis.","authors":"Luigi Pannone, Steffen Uffenorde, Antonia Bosworth Smith, Domenico Giovanni Della Rocca, Pasquale Vergara, Ioannis Doundoulakis, Antonio Sorgente, Alvise Del Monte, Giacomo Talevi, Ingrid Overeinder, Gezim Bala, Alexandre Almorad, Erwin Ströker, Juan Sieira, Ali Gharaviri, Mark La Meir, Pedro Brugada, Andrea Sarkozy, Gian Battista Chierchia, Carlo de Asmundis","doi":"10.36469/001c.133223","DOIUrl":"https://doi.org/10.36469/001c.133223","url":null,"abstract":"Background: Pulmonary vein isolation (PVI) is the main ablation strategy for the treatment of paroxysmal atrial fibrillation. Different technologies are available for PVI, including various cryoballoon catheters (CB-A). Compared with the Arctic Front Advance Pro™, the novel POLARx FIT™ CB-A might reduce costs for atrial fibrillation ablation. Objective: The aim of this study is to perform a health economic evaluation of two cryoballoon systems for PVI procedures. Methods: All patients undergoing their first PVI procedure with POLARx FIT™ CB-A or the Arctic Front Advance Pro™ CB-A were prospectively enrolled. The health economic analysis was performed on the index hospitalization and procedure. The primary safety endpoint included procedure-related adverse events within the index hospitalization. A decision tree model was built to estimate downstream costs. Results: A total of 80 patients with paroxysmal atrial fibrillation undergoing PVI were analyzed, with 40 patients in each arm. Compared with the Arctic Front Advance Pro™ CB-A, POLARx FIT™ CB-A showed a lower procedure time, left-atrium dwell time, and fluoroscopy time. The complication rate was low (6.3%) and included 3 reversible phrenic nerve palsies in the POLARx FIT™ CB-A group vs 2 in the Arctic Front Advance Pro™ CB-A group. Compared with the Arctic Front Advance Pro, the POLARx FIT™ CB-A was associated with lower procedural costs (€2069.7 ± €165.2 vs €2239.5 ± €366.0; P =.009). Conclusion: The POLARx FIT™ CB-A was associated with a shorter procedure time, translating into lower procedural costs, compared with the Arctic Front Advance Pro. Complications were rare and comparable between the two technologies.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"155-161"},"PeriodicalIF":2.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12017263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimating the Fiscal Value of Children Conceived from Assisted Reproduction Technology in Australia Applying a Public Economic Perspective. 从公共经济角度估计澳大利亚辅助生殖技术受孕儿童的财政价值。

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-04-18 eCollection Date: 2025-01-01 DOI: 10.36469/001c.133796

Mark Connolly, Nikos Kotsopoulos, Jinjing Li, Georgina Chambers

{"title":"Estimating the Fiscal Value of Children Conceived from Assisted Reproduction Technology in Australia Applying a Public Economic Perspective.","authors":"Mark Connolly, Nikos Kotsopoulos, Jinjing Li, Georgina Chambers","doi":"10.36469/001c.133796","DOIUrl":"https://doi.org/10.36469/001c.133796","url":null,"abstract":"Background: Public funding for assisted reproduction varies across countries, which can influence the numbers of infertile couples treated annually, and consequently the numbers of children born each year from this technology. As infertility is a medical condition treated within the healthcare system, it must compete against all other medical interventions for funding. This raises questions about how to evaluate a technology that gives rise to human life compared with other healthcare interventions that reduce morbidity and mortality. Objective: To evaluate annual public spending on assisted reproduction technology (ART) in Australia to determine the likely fiscal impact for government over the projected lifetime of an ART-conceived birth cohort. Methods: A public economic framework was used to evaluate the number of children born from ART procedures performed in Australia in 2021 based on projected future lifetime tax contributions and public benefits received. We leveraged data from the Survey of Income and Housing conducted by the Australian Bureau of Statistics and imputations from tax-transfer microsimulations over the lifetime of the cohort estimating cumulative net-taxes. Public spending per pupil for education and lifetime health costs (in Australian dollars) were included in the benefits estimates. Results: We estimated lifetime gross taxes per individual of A <math><mn>841</mn> <mrow><mo> </mo></mrow> <mn>631</mn> <mo>,</mo> <mi>c</mi> <mi>o</mi> <mi>n</mi> <mi>s</mi> <mi>i</mi> <mi>s</mi> <mi>t</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>o</mi> <mi>f</mi> <mi>A</mi></math> 580 182 in direct taxation of earnings and A <math><mn>261</mn> <mrow><mo> </mo></mrow> <mn>448</mn> <mi>i</mi> <mi>n</mi> <mi>c</mi> <mi>o</mi> <mi>n</mi> <mi>s</mi> <mi>u</mi> <mi>m</mi> <mi>p</mi> <mi>t</mi> <mi>i</mi> <mi>o</mi> <mi>n</mi> <mi>t</mi> <mi>a</mi> <mi>x</mi> <mi>e</mi> <mi>s</mi> <mo>.</mo> <mi>A</mi> <mi>f</mi> <mi>t</mi> <mi>e</mi> <mi>r</mi> <mi>d</mi> <mi>e</mi> <mi>d</mi> <mi>u</mi> <mi>c</mi> <mi>t</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>l</mi> <mi>i</mi> <mi>f</mi> <mi>e</mi> <mi>t</mi> <mi>i</mi> <mi>m</mi> <mi>e</mi> <mi>t</mi> <mi>r</mi> <mi>a</mi> <mi>n</mi> <mi>s</mi> <mi>f</mi> <mi>e</mi> <mi>r</mi> <mi>s</mi> <mi>r</mi> <mi>e</mi> <mi>c</mi> <mi>e</mi> <mi>i</mi> <mi>v</mi> <mi>e</mi> <mi>d</mi> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>A</mi> <mi>R</mi> <mi>T</mi> <mi>t</mi> <mi>r</mi> <mi>e</mi> <mi>a</mi> <mi>t</mi> <mi>m</mi> <mi>e</mi> <mi>n</mi> <mi>t</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mo>,</mo> <mi>a</mi> <mi>n</mi> <mi>A</mi> <mi>R</mi> <mi>T</mi> <mo>-</mo> <mi>c</mi> <mi>o</mi> <mi>n</mi> <mi>c</mi> <mi>e</mi> <mi>i</mi> <mi>v</mi> <mi>e</mi> <mi>d</mi> <mi>c</mi> <mi>h</mi> <mi>i</mi> <mi>l</mi> <mi>d</mi> <mi>w</mi> <mi>a</mi> <mi>s</mi> <mi>p</mi> <mi>r</mi> <mi>o</mi> <mi>j</mi> <mi>e</mi> <mi>c</mi> <mi>t</mi> <mi>e</mi> <mi>d</mi> <mi>t</mi> <mi>o</mi> <mi>g</mi> <m","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"148-154"},"PeriodicalIF":2.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Article Correction: We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It? 文章更正：我们正处于突破1型糖尿病治疗的边缘，但200万美国人是谁？

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-04-18 eCollection Date: 2025-01-01 DOI: 10.36469/001c.134140

Rebecca Smith, Samara Eisenberg, Aaron Turner-Phifer, Jacqueline LeGrand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson

引用次数: 0

Unveiling the Public Economic Burden of Migraine in Argentina. 揭示阿根廷偏头痛的公共经济负担。

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-04-09 eCollection Date: 2025-01-01 DOI: 10.36469/001c.133639

Zrinka Orlović, Lucila Rey-Ares, María Florencia Viozzi, Rui Martins, Juliana Villarreal Ramírez, Santiago Veiga, Mark P Connolly

{"title":"Unveiling the Public Economic Burden of Migraine in Argentina.","authors":"Zrinka Orlović, Lucila Rey-Ares, María Florencia Viozzi, Rui Martins, Juliana Villarreal Ramírez, Santiago Veiga, Mark P Connolly","doi":"10.36469/001c.133639","DOIUrl":"https://doi.org/10.36469/001c.133639","url":null,"abstract":"Background: Migraine is a prevalent, underdiagnosed, highly debilitating neurological condition that affects individuals' quality of life and often negatively influences normal daily activities. Objectives: The study objective is to estimate the economic burden of migraine to the Argentine government by assessing the impact of the disease on tax revenue, absenteeism, and social support transfers. Methods: The analysis combines a cross-sectional model utilizing national demographic data and published migraine prevalence rates to estimate the annual burden for the entire migraine-affected cohort, and a longitudinal model assessing the average burden per individual from the age of 40, over a 20-year horizon. A fiscal framework based on generational accounting evaluated the impact of migraine on government finances. Sources of revenue such as direct and indirect taxes were weighted against elements of public expenditure (public sector absenteeism, healthcare expenses, and financial support) and compared with the general population. The effect of migraine on occupational outcomes was sourced from peer-reviewed publications, and costs were sourced from national databases. Results were reported as incremental fiscal consequences (2023 US dollars) and were discounted at 3% annually. Results: The fiscal burden of migraine in Argentina was estimated to be <math><mn>6505</mn> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mi>i</mi> <mi>n</mi> <mi>d</mi> <mi>i</mi> <mi>v</mi> <mi>i</mi> <mi>d</mi> <mi>u</mi> <mi>a</mi> <mi>l</mi> <mi>a</mi> <mi>n</mi> <mi>d</mi></math> 1237 million across the entire migraine population. Annually, 29% of government costs were due to public sector absenteeism, 39% related to healthcare costs, 19% to foregone direct and indirect tax revenue, and 12% to foregone corporation taxes. Additional government transfers represented a minor contribution to the overall fiscal impact of migraine in Argentina. Discussion: The high rate of informal employment is likely to undermine disease burden estimates. Gender disparities were notable, with women bearing 76% of the burden, highlighting the need for gender-specific interventions. Conclusions: This study reveals a significant economic burden of migraine to the Argentinian government, primarily driven by absenteeism, healthcare costs, and foregone tax contributions. Targeted, gender-responsive healthcare and labor policies, especially for sectors with high informal employment, could help reduce these fiscal impacts.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"129-137"},"PeriodicalIF":2.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

People and Families Affected by Glycogen Storage Disease Type Ia: An Analysis of Narrative Accounts Written by Individuals Living with GSDIa and Their Caregivers. 受Ia型糖原储存病影响的人和家庭：GSDIa患者及其照护者所写的叙述分析

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-04-03 eCollection Date: 2025-01-01 DOI: 10.36469/001c.131811

Eliza Kruger, Hayley M de Freitas, Iris Ferrecchia, Millie Gaydon, Andrew Lloyd

{"title":"People and Families Affected by Glycogen Storage Disease Type Ia: An Analysis of Narrative Accounts Written by Individuals Living with GSDIa and Their Caregivers.","authors":"Eliza Kruger, Hayley M de Freitas, Iris Ferrecchia, Millie Gaydon, Andrew Lloyd","doi":"10.36469/001c.131811","DOIUrl":"10.36469/001c.131811","url":null,"abstract":"Background: Glycogen storage disease type Ia (GSDIa) is a rare inherited disorder that can lead to renal and hepatic complications, brain damage, and death. There is a lack of qualitative research describing the impact of GSDIa on individuals and their caregivers. Objective: This study was designed to describe the individual experiences of those affected by GSDIa through qualitative methods. Methods: Individuals with GSDIa and caregivers were recruited through two patient associations (US, UK). Participants were asked to write narratives about their experiences with GSDIa in their own words, with no set questions or topics. The resulting narrative accounts were analyzed thematically using a primarily inductive approach. Themes describing the impact of GSDIa on individuals and caregivers were identified. Results: Eight caregivers, three of whom had lost a child to GSDIa, and 11 individuals living with GSDIa provided written summaries of their experiences of life with the condition. Participants described symptoms, the burden of managing frequent cornstarch feeds, and the broader impacts of GSDIa. These included effects on daily activities, family, emotional and social functioning, romantic relationships, and educational/professional impacts. Participants also described challenges related to obtaining diagnosis and support, and the lack of GSDIa knowledge from healthcare professionals. Discussion: This study provided novel insights into the impact of GSDIa on individuals living with the condition and their caregivers. Participants reported a wide range of issues in their narratives and openly shared sensitive information about their experiences, which may not have been captured if they had taken part in a semi-structured interview format. Conclusion: The narrative method yielded a rich data set that provided details of the varied and individual experiences of GSDIa not captured by traditional quantitative methods or structured interviews. The narratives highlighted the unmet needs of both caregivers of and patients with GSDIa around cornstarch management, obstacles to proper treatment from healthcare professionals, and the absence of effective treatments. The open-ended narrative approach had advantages over standard qualitative methods to capture greater insight into individual experiences directly from participants in their own words.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"120-128"},"PeriodicalIF":2.3,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-Effectiveness Analysis of a Heart Failure Management System in the United States. 美国心力衰竭管理系统的成本-效果分析。

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-03-17 eCollection Date: 2025-01-01 DOI: 10.36469/001c.130066

Antonia Bosworth Smith, Ubong Silas, Alex Veloz, Peter Mallow, Barbara Pisani, Diana Bonderman, Rhodri Saunders

{"title":"Cost-Effectiveness Analysis of a Heart Failure Management System in the United States.","authors":"Antonia Bosworth Smith, Ubong Silas, Alex Veloz, Peter Mallow, Barbara Pisani, Diana Bonderman, Rhodri Saunders","doi":"10.36469/001c.130066","DOIUrl":"10.36469/001c.130066","url":null,"abstract":"Background: The disease burden of heart failure is mainly driven by high hospital readmission rates. Remote monitoring devices can be used to assess the status of patients after discharge and identify early signs of worsening symptoms. Initial studies indicated that Heart Failure Management System (HFMS), a novel monitoring device, can prevent hospital readmission. Objective: To determine the cost effectiveness of HFMS compared with standard of care (SOC) in the United States. Methods: A Markov model was developed to follow patients after their discharge from index hospitalization for heart failure. The costs and outcomes were estimated for 5 years. The patient cohort was initially in \"outpatient care,\" where they are at risk of an emergency room visit or hospital readmission. If hospitalized, patients returned to a second outpatient care health state. An \"escalation of care\" (eg, surgical intervention) may have removed patients from the intervention. The model took the payer perspective with costs in 2022 US dollars. The incremental cost-effectiveness ratio measured effectiveness through hospital readmissions. The willingness-to-pay threshold was set to the published cost of a heart failure rehospitalization ($10 737). Sensitivity and scenario analyses explored the robustness of the model to changes in inputs. Results: Compared with SOC, HFMS reduced the mean cost of care by <math><mn>6723</mn> <mo>(</mo></math> 155 122 vs $161 846) over the 5-year period. The mean number of hospital readmissions was reduced to 1.075 with HFMS from 1.201 with SOC (-0.126 events). The incremental cost-effectiveness ratio showed that HFMS was a dominant strategy compared with SOC, leading to reduced costs and hospital readmissions in 93.4% of the 1000 Monte Carlo simulations; 94.1% of the simulations fell below the willingness-topay threshold. Savings with HFMS emerged from the third month. Discussion: The results indicated the cost-effectiveness of HFMS compared with SOC. The sensitivity analyses supported this finding. Reducing costly hospital readmissions may help to alleviate the burden of heart failure. Longer-term data on HFMS are encouraged to confirm or contest the model outcomes. Conclusions: The use of HFMS is expected to save costs and reduce hospitalizations over a 5-year period compared with the current SOC.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"113-119"},"PeriodicalIF":2.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia. 沙特阿拉伯转移性结直肠癌患者一线西妥昔单抗或帕尼单抗相关的不良事件管理成本

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-03-07 eCollection Date: 2025-01-01 DOI: 10.36469/001c.130878

Gihan Elsisi, Hana Abdul Kareem, Abdelaziz Alaseiri, Abdullah Alsharm, Mohamed Al Garni, Hajer Al-Mudaiheem, Fouad Alnagar, Hazem Lotfy, Mohamed Ouda, Ahmed Elshehri

{"title":"Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia.","authors":"Gihan Elsisi, Hana Abdul Kareem, Abdelaziz Alaseiri, Abdullah Alsharm, Mohamed Al Garni, Hajer Al-Mudaiheem, Fouad Alnagar, Hazem Lotfy, Mohamed Ouda, Ahmed Elshehri","doi":"10.36469/001c.130878","DOIUrl":"10.36469/001c.130878","url":null,"abstract":"Introduction: In Saudi Arabia, patients with metastatic colorectal cancer (mCRC) with wild-type RAS mutations may be treated with either cetuximab plus chemotherapy (CET + CT) or panitumumab plus chemotherapy (PAN + CT), which are epidermal growth factor receptor (EGFR) antibodies. This study calculated the costs of adverse event (AE) management linked to anti-EGFR treatment in Saudi Arabia's national health budget from payer and societal perspectives. Methods: An adaptation of a global model developed in Microsoft Excel® was performed to estimate the costs of AE management associated with the first-line treatment (CET + CT and PAN + CT) of RAS wild-type mCRC patients in Saudi healthcare settings. The frequencies of common and highly common AEs were sourced from the summaries of product characteristics of CET and PAN, whereas AE severity was captured from a meta-analysis. Unit costs in Saudi Riyal (SAR) were obtained from the National Guard of Health Affairs and Ministry of Health 2024 price lists. The model assumptions, inputs, and results were validated using a local Delphi panel. Results: Within the Saudi payer perspective model, treatment with CET + CT vs PAN + CT resulted in average population cost savings of SAR 9 246 133 (4 741 606 international dollars [Intl <math><mo>]</mo> <mo>)</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mo>-</mo> <mi>p</mi> <mi>a</mi> <mi>t</mi> <mi>i</mi> <mi>e</mi> <mi>n</mi> <mi>t</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>s</mi> <mi>o</mi> <mi>f</mi> <mi>S</mi> <mi>A</mi> <mi>R</mi> <mn>20</mn> <mrow><mo> </mo></mrow> <mn>321</mn> <mo>(</mo> <mi>I</mi> <mi>n</mi> <mi>t</mi> <mi>l</mi></math> 10 421) for severe AEs, and average population cost savings of SAR 16 039 427 (Intl <math><mn>8</mn> <mrow><mo> </mo></mrow> <mn>225</mn> <mrow><mo> </mo></mrow> <mn>347</mn> <mo>)</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mo>-</mo> <mi>p</mi> <mi>a</mi> <mi>t</mi> <mi>i</mi> <mi>e</mi> <mi>n</mi> <mi>t</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>s</mi> <mi>o</mi> <mi>f</mi> <mi>S</mi> <mi>A</mi> <mi>R</mi> <mn>35</mn> <mrow><mo> </mo></mrow> <mn>251</mn> <mo>(</mo> <mi>I</mi> <mi>n</mi> <mi>t</mi> <mi>l</mi></math> 18 077) for all-grade AEs. On the other hand, within the Saudi societal perspective model, treatment with CET + CT vs PAN + CT resulted in average population cost savings of SAR 11 386 314 (Intl <math><mn>5</mn> <mrow><mo> </mo></mrow> <mn>839</mn> <mrow><mo> </mo></mrow> <mn>135</mn> <mo>)</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mo>-</mo> <mi>p</mi> <mi>a</mi> <mi>t</mi> <mi>i</mi> <mi>e</mi> <mi>n</mi> <mi>t</mi> <mi>c</mi> <mi>o</mi> <mi>s</mi> <mi>t</mi> <mi>s</mi> <mi>a</mi> <mi>v</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>s</mi> <mi>o</mi> <mi>f</","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"106-112"},"PeriodicalIF":2.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia. 法利昔单抗治疗哥伦比亚糖尿病性黄斑水肿和新生血管性年龄相关性黄斑变性的成本-效果和预算影响分析

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-03-04 eCollection Date: 2025-01-01 DOI: 10.36469/001c.129832

Daniel Samacá-Samacá, Antonio Robles, Hugo Ocampo, Francisco J Rodríguez, Carolina Sardi-Correa, Laura Prieto-Pinto, Christian Bührer, Camilo Tamayo, David Rodríguez, Mauricio Hernández-Quintana

{"title":"Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia.","authors":"Daniel Samacá-Samacá, Antonio Robles, Hugo Ocampo, Francisco J Rodríguez, Carolina Sardi-Correa, Laura Prieto-Pinto, Christian Bührer, Camilo Tamayo, David Rodríguez, Mauricio Hernández-Quintana","doi":"10.36469/001c.129832","DOIUrl":"10.36469/001c.129832","url":null,"abstract":"Background: Retinal diseases are major contributors to disability, significantly affecting patients' quality of life. Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic burden in Colombia. Assessing the economic evaluation of available treatments is essential for the efficient allocation of healthcare resources. Objective: To estimate the cost-effectiveness and budget impact of using faricimab for the treatment of patients with DME and nAMD within the Colombian health system. Methods: This study used a 25-year Markov cohort model to estimate the cost-effectiveness of faricimab vs aflibercept, ranibizumab, and brolucizumab. We used the methodological guidelines of the local health technology assessment agency for conducting the cost-effectiveness and budget impact analysis. Transition probabilities and injection frequencies were derived from the literature. Drug prices were retrieved from public local databases. Quality-adjusted life years (QALYs) were assessed. The potential patient population for the budget impact analysis was estimated based on disease prevalence and expert consultations. Results: Faricimab treat-and-extend (T&E) was dominant vs aflibercept T&E (+0.22 QALYs), ranibizumab T&E (+0.55 QALYs), and brolucizumab for 8 to 12 weeks (+0.06 QALYs) in DME, generating cost savings (in US dollars) of <math><mn>3849</mn> <mo>,</mo></math> 1375, and <math><mn>2824</mn> <mo>,</mo> <mi>r</mi> <mi>e</mi> <mi>s</mi> <mi>p</mi> <mi>e</mi> <mi>c</mi> <mi>t</mi> <mi>i</mi> <mi>v</mi> <mi>e</mi> <mi>l</mi> <mi>y</mi> <mo>.</mo> <mi>I</mi> <mi>n</mi> <mi>n</mi> <mi>A</mi> <mi>M</mi> <mi>D</mi> <mo>,</mo> <mi>f</mi> <mi>a</mi> <mi>r</mi> <mi>i</mi> <mi>c</mi> <mi>i</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mi>a</mi> <mi>l</mi> <mi>s</mi> <mi>o</mi> <mi>s</mi> <mi>h</mi> <mi>o</mi> <mi>w</mi> <mi>e</mi> <mi>d</mi> <mi>d</mi> <mi>o</mi> <mi>m</mi> <mi>i</mi> <mi>n</mi> <mi>a</mi> <mi>n</mi> <mi>c</mi> <mi>e</mi> <mi>v</mi> <mi>s</mi> <mi>a</mi> <mi>f</mi> <mi>l</mi> <mi>i</mi> <mi>b</mi> <mi>e</mi> <mi>r</mi> <mi>c</mi> <mi>e</mi> <mi>p</mi> <mi>t</mi> <mi>a</mi> <mi>s</mi> <mi>n</mi> <mi>e</mi> <mi>e</mi> <mi>d</mi> <mi>e</mi> <mi>d</mi> <mo>(</mo> <mo>+</mo> <mn>0.12</mn> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>s</mi> <mo>)</mo> <mo>,</mo> <mi>r</mi> <mi>a</mi> <mi>n</mi> <mi>i</mi> <mi>b</mi> <mi>i</mi> <mi>z</mi> <mi>u</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mi>a</mi> <mi>s</mi> <mi>n</mi> <mi>e</mi> <mi>e</mi> <mi>d</mi> <mi>e</mi> <mi>d</mi> <mo>(</mo> <mo>+</mo> <mn>0.05</mn> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>s</mi> <mo>)</mo> <mo>,</mo> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>b</mi> <mi>r</mi> <mi>o</mi> <mi>l</mi> <mi>u</mi> <mi>c</mi> <mi>i</mi> <mi>z</mi> <mi>u</mi> <mi>m</mi> <mi>a</mi> <mi>b</mi> <mn>8</mn> <mi>t</mi> <mi>o</mi> <mn>12</mn> <mi>w</mi> <mi>e</mi> <mi>e</mi> <mi>k</mi> <mi>s</mi> <mo>(</mo> <mo>+</mo>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"97-105"},"PeriodicalIF":2.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Dobbs v. Jackson Women's Health Organization on Clinical Diagnosis of Postpartum Depression. Dobbs诉Jackson妇女健康组织对产后抑郁症临床诊断的影响。

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.36469/001c.129633

Onur Baser, Yuanqing Lu, Facundo Sepulveda, Ariani Alemzadeh, Amy Endrizal

{"title":"The Effect of Dobbs v. Jackson Women's Health Organization on Clinical Diagnosis of Postpartum Depression.","authors":"Onur Baser, Yuanqing Lu, Facundo Sepulveda, Ariani Alemzadeh, Amy Endrizal","doi":"10.36469/001c.129633","DOIUrl":"https://doi.org/10.36469/001c.129633","url":null,"abstract":"Background: The 2022 US Supreme Court decision in Dobbs v. Jackson Women's Health Organization eliminated the constitutional right to abortion and activated trigger laws in 21 states, either banning or significantly restricting abortion access. This study estimated changes in postpartum depression (PPD) diagnoses after Dobbs in states with trigger laws vs those without. Methods: Medicaid data from Kythera Labs spanning December 2019 to June 2024 were utilized. Difference-in-difference models assessed changes in PPD diagnosis rates post-Dobbs (21 trigger states, 29 non-trigger states). Results: Women in trigger states were younger (mean, 26.53 vs 27.98 years), more likely to reside in low socioeconomic status areas (41.28% vs 24.42%) and less likely to have obstetrical complications (66.06% vs 77.36%), maternal complications (16.41% vs 18.9%), and lifestyle risk factors (13.58% vs 21.17%). Baseline PPD diagnosis rates were 8.51% in trigger states and 12.66% in non-trigger states. Post-Dobbs, PPD diagnosis rates were 10.20% in trigger states and 14.34% in non-trigger states. Conclusions: Overall, women in states with abortion trigger laws experienced a small positive but statistically insignificant increase in PPD diagnoses following Dobbs compared with those in non-trigger states.","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"86-96"},"PeriodicalIF":2.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan. 日本尼马特利韦/利托那韦与莫努匹拉韦在进展为严重COVID-19高风险患者中的成本-效果分析

IF 2.3

Journal of Health Economics and Outcomes Research Pub Date : 2025-02-24 eCollection Date: 2025-01-01 DOI: 10.36469/001c.129067

Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, Tendai Mugwagwa, Yuki Kado, Mizuki Yoshida, Koichi Murata, Yoshiaki Gu

{"title":"Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan.","authors":"Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, Tendai Mugwagwa, Yuki Kado, Mizuki Yoshida, Koichi Murata, Yoshiaki Gu","doi":"10.36469/001c.129067","DOIUrl":"10.36469/001c.129067","url":null,"abstract":"Background: Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of progression to severe disease in Japan. Objective: This study evaluated, from a Japanese payer perspective, the cost-effectiveness of NMV/r compared with molnupiravir among patients with COVID-19. Methods: This cost-effectiveness model describes the COVID-19 disease history and the impact of antiviral treatment on short-term and long-term outcomes. Nirmatrelvir/ritonavir was compared with molnupiravir, and in the scenario analysis NMV/r was compared with standard of care over a lifetime horizon. Results: When compared with molnupiravir, NMV/r showed higher quality-adjusted life years (QALYs) (15.752 vs 15.739) and higher total cost (¥6 248 014 vs ¥6 245 829 [US <math><mn>44</mn> <mrow><mo> </mo></mrow> <mn>136.86</mn> <mi>v</mi> <mi>s</mi></math> 44 121.42]). The incremental cost-effectiveness ratio was ¥164 934 (US <math><mn>1165.12</mn> <mo>)</mo> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>g</mi> <mi>a</mi> <mi>i</mi> <mi>n</mi> <mi>e</mi> <mi>d</mi> <mo>,</mo> <mi>w</mi> <mi>h</mi> <mi>i</mi> <mi>c</mi> <mi>h</mi> <mi>w</mi> <mi>a</mi> <mi>s</mi> <mi>l</mi> <mi>o</mi> <mi>w</mi> <mi>e</mi> <mi>r</mi> <mi>t</mi> <mi>h</mi> <mi>a</mi> <mi>n</mi> <mi>t</mi> <mi>h</mi> <mi>e</mi> <mi>w</mi> <mi>i</mi> <mi>l</mi> <mi>l</mi> <mi>i</mi> <mi>n</mi> <mi>g</mi> <mi>n</mi> <mi>e</mi> <mi>s</mi> <mi>s</mi> <mo>-</mo> <mi>t</mi> <mi>o</mi> <mo>-</mo> <mi>p</mi> <mi>a</mi> <mi>y</mi> <mo>(</mo> <mi>W</mi> <mi>T</mi> <mi>P</mi> <mo>)</mo> <mi>t</mi> <mi>h</mi> <mi>r</mi> <mi>e</mi> <mi>s</mi> <mi>h</mi> <mi>o</mi> <mi>l</mi> <mi>d</mi> <mi>i</mi> <mi>n</mi> <mi>J</mi> <mi>a</mi> <mi>p</mi> <mi>a</mi> <mi>n</mi> <mo>(</mo> <mrow><mo>¥</mo></mrow> <mn>5</mn> <mrow><mo> </mo></mrow> <mn>000</mn> <mrow><mo> </mo></mrow> <mn>000</mn> <mrow><mo>/</mo></mrow> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mo>[</mo> <mi>U</mi> <mi>S</mi></math> 35 320.71/QALY]). In the scenario analysis, the incremental cost-effectiveness ratio was ¥3 646 821 (US <math><mn>25</mn> <mrow><mo> </mo></mrow> <mn>761.66</mn> <mo>)</mo> <mi>p</mi> <mi>e</mi> <mi>r</mi> <mi>Q</mi> <mi>A</mi> <mi>L</mi> <mi>Y</mi> <mi>g</mi> <mi>a</mi> <mi>i</mi> <mi>n</mi> <mi>e</mi> <mi>d</mi> <mo>.</mo> <mi>O</mi> <mi>n</mi> <mi>e</mi> <mo>-</mo> <mi>w</mi> <mi>a</mi> <mi>y</mi> <mi>s</mi> <mi>e</mi> <mi>n</mi> <mi>s</mi> <mi>i</mi> <mi>t</mi> <mi>i</mi> <mi>v</mi> <mi>i</mi> <mi>t</mi> <mi>y</mi> <mi>a</mi> <mi>n</mi> <mi>a</mi> <mi>l</mi> <mi>y</mi> <mi>s</mi> <mi>i</mi> <mi>s</mi> <mi>a</mi> <mi>n</mi> <mi>d</mi> <mi>p</mi> <mi>r</mi> <mi>o</mi> <mi>b</mi> <mi>a</mi> <mi>b</mi> <mi>i</mi> <mi>l</mi> <mi>i</mi> <mi>s</mi> <mi>t</mi> <mi>i</mi> <mi>c</mi> <mi>s</mi> <mi>e</mi> <mi>n</mi> <mi>s</mi> <mi>i</mi> <mi>t</mi> <mi>i</mi> <mi>v</mi> <mi>i</","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"12 1","pages":"75-85"},"PeriodicalIF":2.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0